Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX Q2 revenue rises 10% to $1,217 million; EPS up 18% to $4.27

Positive Impact 4 of 5 earnings Written later

IDEXX reported second quarter 2026 revenue of $1,217 million, up 10% as reported and 9% organic, and diluted EPS of $4.27, up 18%. The company raised its 2026 EPS outlook to $14.69 to $14.94 from $14.45 to $14.90 and narrowed its full-year revenue guidance to $4,700 million to $4,745 million, which is $5 million higher at the midpoint.

Key points

  • Q2 revenue of $1,217 million, up 10% as reported and 9% organic; CAG Diagnostics recurring revenue up 11% as reported
  • Q2 EPS of $4.27, up 18% as reported and 15% comparable; includes $0.14 per share from share-based compensation tax benefits and $0.06 from currency
  • 2026 EPS outlook raised to $14.69 to $14.94, from $14.45 to $14.90 previously
  • Q2 operating margin of 35.0%, up 140 basis points as reported; 1,600 IDEXX inVue Dx placements in the quarter

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECAug 4, 2026, 6:32 AM ET
Accession number0001104659-26-090033

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.